1. Home
  2. KPTI vs BW Comparison

KPTI vs BW Comparison

Compare KPTI & BW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • BW
  • Stock Information
  • Founded
  • KPTI 2008
  • BW 1867
  • Country
  • KPTI United States
  • BW United States
  • Employees
  • KPTI N/A
  • BW N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • BW Building Products
  • Sector
  • KPTI Health Care
  • BW Industrials
  • Exchange
  • KPTI Nasdaq
  • BW Nasdaq
  • Market Cap
  • KPTI 44.5M
  • BW 45.3M
  • IPO Year
  • KPTI 2013
  • BW N/A
  • Fundamental
  • Price
  • KPTI $4.20
  • BW $0.72
  • Analyst Decision
  • KPTI Buy
  • BW Buy
  • Analyst Count
  • KPTI 6
  • BW 2
  • Target Price
  • KPTI $48.50
  • BW $3.50
  • AVG Volume (30 Days)
  • KPTI 86.5K
  • BW 1.8M
  • Earning Date
  • KPTI 05-12-2025
  • BW 05-12-2025
  • Dividend Yield
  • KPTI N/A
  • BW N/A
  • EPS Growth
  • KPTI N/A
  • BW N/A
  • EPS
  • KPTI N/A
  • BW N/A
  • Revenue
  • KPTI $142,126,000.00
  • BW $734,239,000.00
  • Revenue This Year
  • KPTI $2.34
  • BW $9.70
  • Revenue Next Year
  • KPTI $13.81
  • BW $10.16
  • P/E Ratio
  • KPTI N/A
  • BW N/A
  • Revenue Growth
  • KPTI 1.19
  • BW 12.90
  • 52 Week Low
  • KPTI $3.51
  • BW $0.22
  • 52 Week High
  • KPTI $17.40
  • BW $2.99
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 35.16
  • BW 54.45
  • Support Level
  • KPTI $4.33
  • BW $0.68
  • Resistance Level
  • KPTI $4.65
  • BW $0.79
  • Average True Range (ATR)
  • KPTI 0.47
  • BW 0.11
  • MACD
  • KPTI -0.12
  • BW -0.00
  • Stochastic Oscillator
  • KPTI 8.95
  • BW 35.04

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.

Share on Social Networks: